SCHEMBL169333

SCHEMBL169333

C=CCC(=O)S(=O)(=O)CC=C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7848594 0.80 TSHR (0.32)
SCHEMBL7853498 0.76 TSHR (0.30)
SCHEMBL2659212 0.74
SCHEMBL170595 0.73 TSHR (0.32)
SCHEMBL1840425 0.72
SCHEMBL27654347 0.72
SCHEMBL5705224 0.72
SCHEMBL3191590 0.72
SCHEMBL27448399 0.69
SCHEMBL11667238 0.68 ALOX15 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4215182-A1 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Afferent Pharmaceuticals Inc. (US) 2023-07-26 EP claimed
EP-3865134-A1 METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE AND SUB-ACUTE COUGH, URGE TO COUGH AND CHRONIC COUGH, IN RESPIRATORY DISEASES Afferent Pharmaceuticals Inc. (US) 2021-08-18 EP claimed
EP-3355889-A1 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Afferent Pharmaceuticals Inc. (US) 2018-08-08 EP claimed
EP-3212636-A1 NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2017-09-06 EP claimed
US-20160263112-A1 SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH Afferent Pharmaceuticals, Inc. (US) 2016-09-15 US claimed
EP-3035932-A1 DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH Afferent Pharmaceuticals Inc. (US) 2016-06-29 EP claimed
WO-2016066664-A1 NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2016-05-06 WO claimed
WO-2015027212-A1 DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH AFFERENT PHARMACEUTICALS INC. (US) 2015-02-26 WO claimed
US-20150057299-A1 Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases Afferent Pharmaceuticals, Inc. 2015-02-26 US claimed
EP-1412343-B1 COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS ORION CORP (FI) 2006-08-30 EP claimed
US-20020045758-A1 Pesticidal 1-arylpyrazoles RHONE-POULENC INC. 2002-04-18 US claimed
EP-3212636-B1 NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2023-11-29 EP disclosed
EP-4215182-A1 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Afferent Pharmaceuticals Inc. (US) 2023-07-26 EP disclosed
US-20220143015-A1 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Afferent Pharmaceuticals, Inc. (US) 2022-05-12 US disclosed
EP-3981406-A1 METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS Afferent Pharmaceuticals Inc. (US) 2022-04-13 EP disclosed
WO-2005113552-A1 SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION BAYER HEALTHCARE AG (DE) 2005-12-01 WO disclosed
WO-2005047294-A1 MACROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-05-26 WO disclosed
WO-2004096778-A1 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES BAYER HEALTHCARE AG (DE) 2004-11-11 WO disclosed
US-4182733-A REACTING PHOSPHORIC ACID ESTER WITH HALOGENATING AGENT AND AN OLEFIN BAYER AKTIENGESELLSCHAFT (DE) 1980-01-08 US disclosed
US-4138452-A INTERMEDIATES FOR INSECTICIDES AND FLAMEPROOFING AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1979-02-06 US disclosed